EPITHELIAL OVARIAN CANCER

This study looked at how well the drug niraparib works and its safety in Korean women with ovarian cancer. Researchers followed 850 patients who took niraparib as maintenance therapy or later treatment. They measured how long patients lived without their cancer getting worse and …

This study tested a new drug called RC88 in 43 women whose ovarian, fallopian tube, or peritoneal cancer had stopped responding to platinum-based chemotherapy. The goal was to see if RC88 could shrink tumors and how safe it was. Participants had already tried at least three other…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, …

This early-phase trial tested an experimental drug called SL-172154 combined with either standard chemotherapy or a targeted therapy in 86 people with ovarian cancer that stopped responding to platinum-based treatments. The main goals were to check safety and find the best dose. …

This early-phase study tested a combination of two experimental drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study looked for DNA markers in the blood that could help detect a common and aggressive type of ovarian cancer earlier. Researchers compared blood and tissue samples from 10 women with and without the disease. The goal is to develop a simple blood test for earlier diagnosis…

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how their tumor's genetic makeup relates to their disease. Researchers collected tumor samples and medical data to find links between specific gene changes and how long patients st…

This study aimed to create a blood test that could predict when ovarian, peritoneal, or fallopian tube cancer might come back. Researchers looked for specific protein patterns, called a 'fingerprint,' in the blood of 119 women whose cancer was in remission. Participants had regul…

This study reviewed medical records of 51 women with ovarian, fallopian tube, or primary peritoneal cancer who received the drug rucaparib in regular clinical practice in Spain. Researchers looked at patient history, side effects, dosing, and how well the drug controlled the canc…